Anyway, since sTNFR2 exerts a neuroprotective function and promotes tissue regeneration [67,68], the TNF-α unchanged levels that we observed in the MS patients after antioxidant treatment may be a way to support the TNF-α immunomodulation. This evidence concerns the gene TNF and myeloid sarcoma.